These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2825 related articles for article (PubMed ID: 19317993)

  • 1. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.
    Reed J; Rosman M; Verbanac KM; Mannie A; Cheng Z; Tafra L
    J Am Coll Surg; 2009 Mar; 208(3):333-40. PubMed ID: 19317993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
    Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
    Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN biopsy.
    Rydén L; Chebil G; Sjöström L; Pawlowski R; Jönsson PE
    Eur J Surg Oncol; 2007 Feb; 33(1):33-8. PubMed ID: 17174513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.
    Kiluk JV; Ly QP; Santillan AA; Meade T; Ramos D; Reintgen DS; Dessureault S; Davis M; Shamehdi C; Cox CE
    Ann Surg Oncol; 2010 Feb; 17(2):552-7. PubMed ID: 19957043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection.
    Calhoun KE; Hansen NM; Turner RR; Giuliano AE
    Am J Surg; 2005 Oct; 190(4):588-91. PubMed ID: 16164927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors to assess non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis.
    Jinno H; Sakata M; Asaga S; Wada M; Shimada T; Kitagawa Y; Suzuki T; Nakahara T; Kitamura N; Kubo A; Mukai M; Ikeda T; Kitajima M
    Breast J; 2008; 14(6):551-5. PubMed ID: 19000054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the likelihood of additional nodal metastases in breast carcinoma patients with positive sentinel node biopsy.
    Mustać E; Matusan-Ilijas K; Marijić B; Smokvina M; Jonjić N
    Int J Surg Pathol; 2010 Feb; 18(1):36-41. PubMed ID: 19448065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer.
    Fan YG; Tan YY; Wu CT; Treseler P; Lu Y; Chan CW; Hwang S; Ewing C; Esserman L; Morita E; Leong SP
    Ann Surg Oncol; 2005 Sep; 12(9):705-11. PubMed ID: 16079953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry.
    Chagpar A; Middleton LP; Sahin AA; Meric-Bernstam F; Kuerer HM; Feig BW; Ross MI; Ames FC; Singletary SE; Buchholz TA; Valero V; Hunt KK
    Cancer; 2005 Apr; 103(8):1581-6. PubMed ID: 15747375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel node biopsy and cytokeratin staining for the accurate staging of 478 breast cancer patients.
    Pendas S; Dauway E; Cox CE; Giuliano R; Ku NN; Schreiber RH; Reintgen DS
    Am Surg; 1999 Jun; 65(6):500-5; discussion 505-6. PubMed ID: 10366202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.
    Nogi H; Suzuki M; Kamio M; Kato K; Kawase K; Toriumi Y; Takeyama H; Fukushima H; Morikawa T; Uchida K
    Oncol Rep; 2011 Apr; 25(4):1109-15. PubMed ID: 21308353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
    Shen J; Gilcrease MZ; Babiera GV; Ross MI; Meric-Bernstam F; Feig BW; Kuerer HM; Francis A; Ames FC; Hunt KK
    Cancer; 2007 Apr; 109(7):1255-63. PubMed ID: 17330229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer?
    Teng S; Dupont E; McCann C; Wang J; Bolano M; Durand K; Peltz E; Bass SS; Cantor A; Ku NN; Cox CE
    Am Surg; 2000 Jun; 66(6):574-8. PubMed ID: 10888134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
    Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
    J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer.
    Noguchi M
    Eur J Surg Oncol; 2008 Feb; 34(2):129-34. PubMed ID: 17498911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy is associated with improved survival compared to level I & II axillary lymph node dissection in node negative breast cancer patients.
    Langer I; Guller U; Hsu-Schmitz SF; Ladewig A; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
    Eur J Surg Oncol; 2009 Aug; 35(8):805-13. PubMed ID: 19046846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of isolated tumor cells in sentinel lymph nodes detected by immunohistochemical staining.
    Imoto S; Ochiai A; Okumura C; Wada N; Hasebe T
    Eur J Surg Oncol; 2006 Dec; 32(10):1175-9. PubMed ID: 16979316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary node staging for microinvasive breast cancer: is it justified?
    Lyons JM; Stempel M; Van Zee KJ; Cody HS
    Ann Surg Oncol; 2012 Oct; 19(11):3416-21. PubMed ID: 22576061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 142.